ImpediMed announces departure of long-term chief executive

Latest News

Medical software technology company ImpediMed (ASX:IPD) has announced the departure of its managing director and CEO Richard Carreon.

Mr Carreon has led the company over the past ten years through the research, development and commercialisation of the SOZO Digital Health Platform.

The company said much of its commercial success is based on the largest ever clinical trial conducted in the lymphoedema space. Mr Carreon oversaw PREVENT the trial.

The outcome demonstrated that intervention in patients with early detection of cancer-related lymphoedema using ImpediMed’s L-Dex technology resulted in a lower rate of progression to chronic disease than patients with early detection from volume measurements using a tape measure.

Mr Carreon’s leadership guided the creation of the SOZO Digital Health Platform, said the company. To date, over 880 SOZO units have been sold globally and over 450,000 patient tests have been conducted.

Mr Carreon said, "I am grateful to have spent ten years with this great company. I am very proud of what our teams around the world have accomplished. Together, we have positively impacted the lives of hundreds of thousands of patients and their families. I believe this is the right time for me to step down. The Company is operationally sound and positioned for continued growth. Additionally, we have laid out a vision for the Company that will guide it for many years to come, and this gives me great confidence about ImpediMed's future success.”

“Mr Carreon led the Company through a very transformative time over the past ten years, achieving tremendous success in gaining regulatory clearance for SOZO, initiating commercialisation of ImpediMed’s technology and setting the Company on a path for future success. The entire ImpediMed team thanks him for his contributions and wishes him the best,” said chair Donald Williams.

Current board member David Anderson will assume the role of Interim CEO with Mr Carreon’s departure. Mr Anderson has been a member of ImpediMed’s board of directors since April 2020 and also served in the capacity of Remuneration Committee Chair. He brings over a 30-year history of leadership in the health care and insurance industries and is an expert on reimbursement strategy, a key pillar for ImpediMed’s long-term success.